ATE422366T1 - Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen - Google Patents

Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen

Info

Publication number
ATE422366T1
ATE422366T1 AT03727589T AT03727589T ATE422366T1 AT E422366 T1 ATE422366 T1 AT E422366T1 AT 03727589 T AT03727589 T AT 03727589T AT 03727589 T AT03727589 T AT 03727589T AT E422366 T1 ATE422366 T1 AT E422366T1
Authority
AT
Austria
Prior art keywords
lipopeptides
mixtures
preparing vaccines
relates
vaccines
Prior art date
Application number
AT03727589T
Other languages
English (en)
Inventor
Jean-Gerard Guillet
Isabelle Bourgault-Villada
Marion Dupuis
Masse Helene Gras
Line Bourel
Oleg Melnyk
Pascal Joly
Dominique Bonnet
Frederic Malingue
Jean Cyrille Grand
Bertrand Georges
Original Assignee
Centre Nat Rech Scient
Univ Lille Ii
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Lille Ii, Inst Nat Sante Rech Med filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE422366T1 publication Critical patent/ATE422366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03727589T 2002-03-14 2003-03-14 Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen ATE422366T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0203189A FR2837104B1 (fr) 2002-03-14 2002-03-14 Utilisation de melange de lipopeptides pour la fabrication de vaccins

Publications (1)

Publication Number Publication Date
ATE422366T1 true ATE422366T1 (de) 2009-02-15

Family

ID=27772125

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727589T ATE422366T1 (de) 2002-03-14 2003-03-14 Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen

Country Status (9)

Country Link
EP (1) EP1487484B1 (de)
JP (1) JP2005527513A (de)
AT (1) ATE422366T1 (de)
AU (1) AU2003233377A1 (de)
CA (1) CA2478846A1 (de)
DE (1) DE60326128D1 (de)
ES (1) ES2322253T3 (de)
FR (1) FR2837104B1 (de)
WO (1) WO2003075956A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268287A1 (en) * 2005-11-11 2008-10-30 Elena Donadio Method of Converting Water-Soluble Active Proteins Into Hydrophobic Active Proteins, the Use of the Same for the Preparation of Monomolecular Layers of Oriented Active Proteins, and Devices Comprising the Same
CA2754764A1 (en) * 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
DK2406286T3 (en) 2009-03-10 2016-08-22 Baylor Res Inst Anti-cd40 antibodies and uses thereof
EP3094652B1 (de) 2014-01-13 2021-09-29 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
CN105949121A (zh) * 2016-06-02 2016-09-21 辽宁大学 一种从莲子心中提取甲基莲心碱的方法及其应用
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ， インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
FR3086534B1 (fr) 2018-10-01 2020-11-06 Univ Bordeaux Methode pour traiter une infection par le virus de l'immunodeficience humaine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797632B1 (fr) * 1999-08-19 2003-01-24 Dutel Sa Fonctionnalisation d'un peptide par un groupement alpha- hydrazinoacetique
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
FR2813794B1 (fr) * 2000-09-08 2003-01-24 Pasteur Institut Procede de couplage, en solution, entre un peptide et un vecteur lipophile et ses applications

Also Published As

Publication number Publication date
DE60326128D1 (de) 2009-03-26
CA2478846A1 (fr) 2003-09-18
AU2003233377A2 (en) 2003-09-22
AU2003233377A1 (en) 2003-09-22
FR2837104A1 (fr) 2003-09-19
WO2003075956A2 (fr) 2003-09-18
FR2837104B1 (fr) 2004-08-06
ES2322253T3 (es) 2009-06-18
JP2005527513A (ja) 2005-09-15
EP1487484B1 (de) 2009-02-11
EP1487484A2 (de) 2004-12-22
WO2003075956A3 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
NO20031687D0 (no) Veksthormonsekretagoger
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
DE60324552D1 (en) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
IS7533A (is) Lifrarbólgu C-veirutálmar
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
UA85536C2 (en) Viral antigens
EP1771454A4 (de) Peptidanaloga als hepatitis c-hemmer
TWI367880B (en) Carbazole compounds
ATE422366T1 (de) Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
DK1480998T3 (da) Mellemprodukter og fremgangsmåder til fremstilling af heptapeptidoxytocinanaloger
DE60306636D1 (de) Wachstumhormonsekretionsförderer
ATE414905T1 (de) Diabetesmodell
DK1572615T3 (da) Fremgangsmåde til syntese af peptider indeholdende en 4-hydroxyprolin-substruktur
DE69917813D1 (de) Verbindungen zur verwendung als phosphotyrosinmimetika

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties